Ram Aiyar

Ram Aiyar, Ph.D., MBA, is the Chief Executive Officer and President of Korro Bio, Inc., a biotechnology company specializing in RNA editing therapies. He has nearly two decades of experience in the biotech and pharmaceutical industries, where he has worked across various stages of development, from clinical trials to commercialization.

Career Overview

Before joining Korro Bio in November 2020, Aiyar co-founded Corvidia Therapeutics, where he served as Chief Financial Officer and Chief Business Officer. He played a pivotal role in the company's growth and led its acquisition by Novo Nordisk for $2.1 billion. His previous roles include positions at BioHealth Innovation as an entrepreneur-in-residence, and leadership roles at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase.

Aiyar began his scientific career in research at Janssen Pharmaceuticals' immunology group and has a robust background in corporate development, finance, and strategy.

Education

Ram Aiyar holds a Master of Science (M.S.) and a Ph.D. in Electrical and Computer Engineering from Drexel University, along with an MBA in Finance and Business Strategy from INSEAD (France/Singapore) .123

Contributions to Korro Bio

At Korro Bio, Aiyar is focused on advancing the company's proprietary RNA editing platform, OPERA (Oligonucleotide Promoted Editing of RNA), which aims to treat diseases by repairing mutations at the RNA level. His leadership is expected to drive innovation in genetic medicine, particularly targeting conditions that have been difficult to treat with traditional approaches .24